Vical, Inc.

  • Inovio's Pipeline And Its Rise To Fame

    By Terry Chrisomalis - August 5, 2013 | Tickers: CLDX, INO, VICL

    There are many biotechs which are undervalued,because they are only in trials. But there are times when you can catch , if you look hard enough, at a gem biotech that is trading way below it's current value. This brings me to a biotech stock Inovio Pharmaceuticals Inc. (NYSEMKT: INO) This is one of a few biotech stocks that you can find that has a huge pipeline that trades more »

  • 3 Interesting Immunotherapy Cancer Stocks

    By Mark Holder - June 26, 2013 | Tickers: AMGN, VICL

    As with any treatments dealing with cancer, opportunity exists to drastically improve the survival rates and, as importantly, reduce the side effects caused by surgery and chemotherapy. Several drugs are in different phases of development that focus on a therapeutic approach of using local injections to produce a systemic effect. The products include T-Vec by Amgen (NASDAQ: AMGN), ImmunoPulse by OncoSec Medical (NASDAQ: ONCS), and Allovectin-7 by Vical (NASDAQ: VICLmore »)

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • This Biotech Stock Might Boost Your Portfolio

    By Terry Chrisomalis - April 4, 2013 | Tickers: BMY, GSK, VICL

    There are many promising biotech companies out there to choose from. One such company, named Vical (NASDAQ: VICL), is targeting a cancer known as Melanoma. Melanoma is the most dangerous form of skin cancer, and is the leading cause of death for skin disease. The company has a good pipeline, but its lead candidate is Allovectin. 

    Allovectin approaching results

    Results from a phase 3 trial are approaching for Allovectin. Allovectin more »

  • Is Vical in Romneyland?

    By John Damschroder - November 13, 2012 | Tickers: BMY, VICL

    The shocker of the 2012 campaign is Mitt Romney's mistaken assumption that he had a small lead to protect rather than a small gap to close.  This false premise caused Romney to close the campaign with the tactics that were designed not to lose rather than to win.

    Recent activity in my largest holding, Vical (NASDAQ: VICL) has me wondering if I am also making counter-productive moves that will more »

  • Playing the Immune System for Profit

    By Streetwise Reports - April 20, 2012 | Tickers: BMY, DNDN, GSK, MRK, VICL

    For more interviews with sector experts and analysts, please sign-up for our newsletters at www.TheLifeSciencesReport.com

    -------------

    George S. Mack,  The Life Sciences Report

    Immunotherapies turn the body into a natural manufacturing machine to fight disease.

    I had an opportunity to pose some questions once again to Stephen Dunn, who is president and senior managing director of research at LifeTech Capital, a division of Aurora Capital, which has a presence more »

  • Fighting Infectious Disease, the World's Number Two Killer

    By Streetwise Reports - March 8, 2012 | Tickers: CPHD, OPTR, QDEL, KLH, VICL

    George S. Mack, The Life Sciences Report

    Think beyond cancer for big gains in biotech.

    I'm not alone in thinking that cancers have assumed more than their share of interest from investors. In fact, sometimes it feels like oncology is all biotech and pharma care about. Blood-related cancers and solid tumors account for 13% of deaths worldwide, but a disproportionate 70% of investment dollars flow to oncology research. This more »